Navigation Links
Assured Pharmacy Reports Same Store Sales for the Month of July 2010

FRISCO, Texas, Aug. 19 /PRNewswire-FirstCall/ -- Assured Pharmacy (Pink Sheets: APHY), a leading specialty pharmacy providing prescription medications to more than 3,000 sufferers of chronic pain announced that total sales on a same store basis for the month of July 2010 were $1,422,163 which equates to $67,722 per business day .  This represents an increase of 1.4 percent compared with total sales of $1,402,374 for June 2010 and an increase of 6.2 percent compared with total sales per business day of $63,744 for June 2010.  It also represents an increase of 20.8 percent when compared with total sales of $1,177,551 for the same period one year ago.  

"We are very pleased with our sales results in July which marks our fifth consecutive month of revenue per business day growth.  The results reflect continued progress in the implementation of our strategies, especially when taking into consideration that the summer months have been historically lower revenue months due to seasonality," said Robert DelVecchio, Chief Executive Officer of Assured Pharmacy. "As these sales figures reflect, we remain on track in our drive for sales and market share growth, improved earnings at the store level and strong cash flow.  I believe the transparency of our monthly sales trend is vital to keeping its shareholders informed and have initiated an action plan to inform our shareholders of these sales trends on the third Thursday of each month."

Click Here for Corresponding Video News Release.

About Assured Pharmacy, Inc.Assured Pharmacy, Inc. is engaged in the business of operating specialty pharmacies that primarily dispense highly regulated pain medication. The Company derives its revenue primarily from the sale of prescription drugs and does not keep in inventory non-prescription drugs or health and beauty related products inventoried at traditional pharmacies. The Company offers physicians the ability to electronically transmit prescriptions to its pharmacies. The majority of the Company's business is derived from repeat business from its customers. "Walk-in" prescriptions from physicians are limited. The Company currently has four operating pharmacies. Three of those pharmacies are wholly owned and the Company has a 94.8% ownership interest in the other pharmacy.

Safe Harbor StatementThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934.
These forward-looking statements are based largely on the expectations or forecasts of future events, can be affected by inaccurate assumptions, and are subject to various business risks and known and unknown uncertainties, a number of which are beyond the control of management.
Therefore, actual results could differ materially from the forward-looking statements contained in this press release.
A wide variety of factors that may cause actual results to differ from the forward-looking statements include, but are not limited to, the following: the Company's ability to increase revenue and profits in the current economic climate; the effect of changing economic conditions; lack of sufficient financing for opening new pharmacies; inability to manage growth; and changes in government regulations, controls and similar matters.
These cautionary statements should not be construed as exhaustive or as any admission as to the adequacy of the Company's disclosures.
The Company cannot predict or determine after the fact what factors would cause actual results to differ materially from those indicated by the forward-looking statements or other statements.
The reader should consider statements that include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", "projects", "should", or other expressions that are predictions of or indicate future events or trends, to be uncertain and forward-looking.
The Company does not undertake to publicly update or revise forward-looking statements, whether as a result of new information, future events or otherwise.Investor Contact:Mr. Robert DelVecchioChief Executive OfficerAssured Pharmacy, Inc.(214) 220-9302

SOURCE Assured Pharmacy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CVS/pharmacy Offers Flu Vaccinations in Over 4,000 Stores
2. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
3. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
4. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
5. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
6. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
8. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
9. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
10. Cardinal Health Expands PET Nuclear Pharmacy Services to Support Clinical Drug Trials
11. McGraw-Hill Professional Launches Drug Effectiveness Resource on AccessPharmacy
Post Your Comments:
(Date:11/24/2015)... The hope of bearing a ... IVF cycles. After failure of over 15 IVF cycles, ... all hopes that she would be able to conceive ever. But finally optimism prevailed as ... failure of over 15 IVF cycles. ... take one last attempt with Gaudium IVF Center in ...
(Date:11/24/2015)... CARLOS, Calif. , Nov. 24, 2015 ... a leader in non-invasive genetic testing and ... announced that it will present at the ... in New York on Wednesday, December 2, 2015 at 1:00 p.m. ET.  Matthew ... the Company,s financial results, business activities and ...
(Date:11/24/2015)... 2015 /PRNewswire/ - ESSA Pharma Inc. ("ESSA" or the ... that the first patient has been enrolled in ESSA,s ... for metastatic castration-resistant prostate cancer ("mCRPC"). ... --> the United States and ... clinical trial, ESSA intends to demonstrate the safety, tolerability, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... 24, 2015 , ... In response to recent news highlighting Oxycodone fraud, Novus ... in the United States grew 400 percent between 1999 and 2010, far more than ... 37 percent of all fatal drug overdoses. (1) , While oxycodone and the extended ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... Serenity Point ... a series of recent video interviews with some of the staff members at their ... the residential treatment facility, as well as some of the things that make their ...
(Date:11/24/2015)... ... 2015 , ... Chiropractic student Katie Benson received a $2,500 ... Park, Kansas. Benson, a fifth-trimester student in the university’s College of Chiropractic, accepted ... 16. , “Katie is very excited and greatly appreciative to receive the Standard ...
(Date:11/24/2015)... ... November 24, 2015 , ... Autism Speaks, the world’s leading autism science and ... media and the generosity of people around the world. On December 1, supporters can ... give – and share the personal stories behind those gifts. , Just as ...
(Date:11/24/2015)... ... November 24, 2015 , ... World ... Fragrance by Marcelle, a cosmetic invention which offers a combination of natural essential ... in the US is worth $3 billion annually," says Scott Cooper, CEO and ...
Breaking Medicine News(10 mins):